Med-X, Inc.

Nevada corporation (incorporated February 2014; Canoga Park, California) whose revenue comes from Nature-Cide botanical pest-control products and Thermal-Aid heating and cooling therapy products, sold through distributors and e-commerce; it also owns The Marijuana Times cannabis-media brand from its early years. One of the earliest Regulation A Tier 2 issuers (first qualified November 3, 2015) and a serial retail raiser since: Reg A rounds in 2015-2017, Reg CF at $3.00 in 2024, private placements at $1.60 to $3.00, and a $10 million Reg A Tier 2 offering at $4.00 qualified May 29, 2025 with DealMaker as lead selling agent (6.5% cash fee). FY2025 (Cherry Bekaert LLP, PCAOB standards; FY2024 restated): revenue $1.99 million, net loss $6.96 million, cash $270,079, going-concern substantial doubt; $5.17 million raised from stock sales in 2025. An S-1 for a listed offering was withdrawn in April 2024 without going effective. On September 1, 2026 it disclosed a settlement with GEM Global Yield after a 2021 agreement, under which GEM had committed to buy up to $100 million of stock once Med-X listed, expired unused; the $400,000 settlement is payable only on a listing or alternative transaction, and the agreement states Med-X is targeting a listing or OTC quotation by October 31, 2026. Legal record (company 1-Us): the SEC temporarily suspended its Reg A exemption in September 2016 for a late 2015 annual report; an ALJ vacated the order May 8, 2017, final August 24, 2017. In September 2017 it settled with the California Department of Business Oversight over non-disclosure of an employee's 2010 desist-and-refrain order.

Operating company (consumer and pest-control products) raising retail capital under Reg A Tier 2, Reg CF and Reg D; classified by AltStreet as ordinary operating-company equity, outside its alternative-asset scope.